Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Impact of Force Control of Hip Abductor Muscles in Healthy Adults and Individuals With Parkinson's Disease

4 mai 2026 mis à jour par: Chu-Ling Yen, Chang Gung Memorial Hospital

Impact of Force Control of Hip Abductor Muscles on Postural Control in Middle-aged and Older Adults and Individuals With Parkinson's Disease

Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. While previous studies have mainly focused on sagittal plane balance, the contribution of hip abductor muscles remains unclear, especially regarding their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. Previous studies have mainly focused on sagittal plane balance and have identified the important roles of ankle plantar flexors and knee extensors; however, the contribution of hip abductor muscles-key muscles for frontal plane stability-remains unclear, particularly in terms of their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD. Healthy young, middle-aged, and older adults will be recruited from the community, and individuals with PD will be recruited from the Department of Neurology. Healthy participants must be in good health, able to walk independently, demonstrate normal cognitive function, and provide informed consent, while those with neurological, cardiovascular, musculoskeletal, or other conditions affecting motor performance will be excluded. For individuals with PD, inclusion criteria will be a clinical diagnosis of idiopathic PD, Hoehn and Yahr stages 1 to 3, stable anti-PD medication use, and the ability to follow instructions and walk at least 10 m. Exclusion criteria will include psychiatric, immune, integumentary, or musculoskeletal disorders, neurological conditions other than PD, lower extremity pain, uncontrolled cardiovascular disease, or inability to provide informed consent. All participants will undergo a one-time assessment, including maximal voluntary isometric contraction, force steadiness, postural control, and gait performance.

Surface electromyography will be used to assess neuromuscular function, postural control will be evaluated using a force plate under multiple standing conditions, and gait parameters will be measured at both comfortable and fast walking speeds. Statistical analyses will be conducted using ANOVA to examine group differences.

Type d'étude

Observationnel

Inscription (Estimé)

210

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

  • Taïwan
      • Taoyuan, Taïwan
        • Recrutement
        • Chang Gung Memorial Hospital
        • Contact:
      • Taoyuan, Taïwan
        • Recrutement
        • Chang Gung University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

This study recruits healthy elderly individuals, healthy middle-aged individuals, healthy young individuals, and individuals with PD.

La description

Healthy people

Inclusion Criteria:

  • 20 to 39 years (young), 40 to 59 years (young), and 60-85 years (old)
  • generally in good health
  • able to walk 10 m independently
  • able to follow all instructions

Exclusion Criteria:

  • neurologic, psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
  • any pain over the lower extremities
  • uncontrolled cardiovascular diseases
  • unable to provide informed consent.

PD

Inclusion Criteria:

  • clinical diagnosis of idiopathic PD
  • Hoehn and Yahr stages 1 to 3
  • stable anti-PD medications
  • able to walk 10 m independently
  • able to follow all instructions

Exclusion Criteria:

  • psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
  • neurological conditions other than PD
  • any pain over the lower extremities
  • uncontrolled cardiovascular diseases
  • unable to provide informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Healthy people
General healthy adults
Autre: Age
We compare the young, middle-aged, and old groups
Autre: Parkinson's disease (PD)
We compare the healthy group and PD group.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Maximal force
Délai: Baseline
The maximal force of lower extremity muscles
Baseline
Rate of torque development
Délai: Baseline
The ability to rapidly generate muscle force
Baseline
Force steadiness
Délai: Baseline
The ability to maintain a constant force output during a submaximal contraction
Baseline
Walking speed
Délai: Baseline
The time taken by participants to walk a standardized distance
Baseline
Step Length
Délai: Baseline
The linear distance between the two ankles, typically expressed in centimeter(cm).
Baseline
Cadence
Délai: Baseline
The number of steps taken per minute (SPM)
Baseline
Single Support Time
Délai: Baseline
The duration within the gait cycle when only one foot is in contact with the ground, typically measured in seconds or as a percentage of the total gait cycle.
Baseline
Double Support Time
Délai: Baseline
The portion of the gait cycle where both feet are in contact with the ground, indicating the transition phase between steps, expressed as a percentage of the gait cycle or in seconds.
Baseline
Swing Time
Délai: Baseline
The portion of the gait cycle where the foot is not in contact with the ground, moving forward to the next step. It is usually expressed as a percentage of the total gait cycle or in seconds.
Baseline
Timed Up-and-Go Test
Délai: Baseline
Tthe time an individual takes to stand up from a chair, walk 3 meters, turn around, walk back, and sit down.
Baseline
Four Square Step Test
Délai: Baseline
Participants will be required to perform four square step test by changing directions while stepping forward, sideway, and backward over a low obstacle as fast as possible.
Baseline
Center of Pressure (COP) Velocity in Balance Tasks
Délai: Baseline
The speed at which the COP moves, calculated over the duration of the balance task. Higher velocities may reflect more dynamic balance adjustments or instability. Unit：millimeter per second(mm/s)
Baseline
Center of Pressure (COP) Area in Balance Tasks
Délai: Baseline
The area covered by the COP trajectory during the balance task, providing an estimate of the sway envelope. A larger area might indicate poorer balance control. Unit：square millimeter(mm^2)
Baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Chang Gung Memorial Hospital

Collaborateurs

Chang Gung University

Les enquêteurs

  • Chercheur principal: Chu-Ling Yen, Chang Gung University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 août 2023

Achèvement primaire (Estimé)

31 juillet 2029

Achèvement de l'étude (Estimé)

31 juillet 2029

Dates d'inscription aux études

Première soumission

25 avril 2026

Première soumission répondant aux critères de contrôle qualité

1 mai 2026

Première publication (Réel)

6 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 202202289A3

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner